V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation
11.6.2024 11:00:00 EEST | Business Wire | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/
V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia.
V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video industry, such as MPEG-5 LCEVC and VC-6. It has also developed V-Nova PresenZ, a unique volumetric format that enables cinematic 6 Degrees of Freedom (6DoF) immersive experiences for the first time. Recently, V-Nova has demonstrated how its technologies drive substantial efficiencies and unique use cases in AI media indexing, multimodal Generative AI, and Intelligent Edge applications.
V-Nova’s extensive patent portfolio supports a variety of industries, including Entertainment, Social Media, Streaming, Broadcasting, Cloud Gaming, Virtual and Augmented Reality, Industrial Applications, Automotive, Security, and Defence.
“This milestone in V-Nova’s technology portfolio represents a systemic achievement tied to our company structure, strategic focus, and the highly talented individuals we have brought together,” said Guido Meardi, CEO at V-Nova.
Continuous research and development are a cornerstone of V-Nova’s technology roadmap and its resource allocation. The company has been granted 200 patents in the past 12 months alone, with 9 UK patents granted in under 200 days since the filing date. This rapid pace of innovation highlights the quality of its applications and the dedication of its team.
“V-Nova’s success is a result of its company culture, which supports diversity of opinions and encourages collaboration,” said Stergios Poularakis, Head of Advanced R&D at V-Nova. “Our team brings the right people together to interact, innovate, and create something new and exciting.”
V-Nova’s core IP development includes multi-layer and parallel data coding technology that underpins MPEG-5 LCEVC and VC-6. MPEG-5 LCEVC enables users to implement a new data layer onto an existing codec, improving visual quality, reducing energy consumption during the transcoding process, and enhancing compression efficiency. V-Nova’s innovative approach has recently unlocked new virtual reality and mixed reality use cases. The V-Nova PresenZ format enables photo-realistic immersive experiences at scale, with 6 Degrees of Freedom (6DofF) to allow viewers to ‘step inside’ cinematic content. V-Nova technologies also facilitate AI Media Indexing, Machine Vision, and Large Multimodal Models (LMMs) to interact with data like humans, efficiently processing only the necessary resolution and regions of interest while maintaining the entire signal at maximum quality in efficiently compressed form.
V-Nova continues to invest in innovative research and development. Richard Fish, Patent Attorney at V-Nova commented, “Almost 40% of employees at V-Nova are named as inventors on a patent application, making us one of the most innovative companies in the UK, if not the world.”
About V-Nova
V-Nova is committed to unlocking higher quality digital experiences at scale. Its technologies, including MPEG-5 LCEVC and VC-6, are based on the innovative use of AI and parallel processing, improve data, video, imaging, and point-cloud compression, and have been granted international standard status by MPEG, ISO and SMPTE. V-Nova’s relentless investment in R&D has built a portfolio of over 1000 international patents, along with a range of software products and solutions. More about V-Nova: www.v-nova.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611724561/en/
Contact information
V-Nova Marketing and Communications:
Joao Felix – press@v-nova.com
Bubble Agency - UK & EMEA Account Director:
Danielle Harper – danielleh@bubbleagency.com
Bubble Agency - Head of Americas:
Kim Willsher – Kimw@bubbleagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom